Skip to nav Skip to content
Michael  Shafique

Michael Shafique, MD

4.9 (297)

Specialty: Medical Oncology

Program: Satellite and Community Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Pancoast Tumor, Thymoma

    Dr. Shafique earned his Medical Degree from the University of Virginia School of Medicine and completed an Internal Medicine residency at Duke University Medical Center and a subsequent Hematology and Medical Oncology fellowship at the University of South Florida/Moffitt Cancer Center. Although Dr. Shafique devotes most of his time to treating patients with lung cancer, he also sees patients with a broad spectrum of diagnoses as part of early-phase clinical trials. Additionally, he manages medical oncology treatments for patients with Gynecologic malignancies.  

    Education & Training

    Fellowship:

    • University of South Florida - Hematology and Oncology

    Residency:

    • Duke University Medical Center - Internal Medicine

    Medical School:

    • University of Virginia School of Medicine - MD
  • Publications

    • Perez B, Aljumaily R, Marron TU, Shafique MR, Burris H, Iams WT, Chmura SJ, Luke JJ, Edenfield W, Sohal D, Liao X, Boesler C, Machl A, Seebeck J, Becker A, Guenther B, Rodriguez-Gutierrez A, Antonia SJ. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 2024 Feb.9(2):102217. Pubmedid: 38320431. Pmcid: PMC10937199.
    • Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 2023 Sep.183:107313. Pubmedid: 37499521.
    • Meng L, Cao B, Ji R, Chen DT, Laber DA, Shafique M. Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis. J Cancer. 2023 Sep.14(17):3169-3175. Pubmedid: 37928431. Pmcid: PMC10622985.
    • Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
    • Singh AM, Rubiera-Pebe R, Ahmad Y, Shafique M, Hicks JK, Tanvetyanon T. Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncol Pract. 2023 Jun.19(6):345-351. Pubmedid: 37075260.
    • Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
    • Huang S, Jordan A, Jenneman D, Shafique M, Holmstrom B. Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. Cureus. 2022 Feb.14(2):e22295. Pubmedid: 35350507. Pmcid: PMC8933124.
    • Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith ES, Mishra V, Schröder A, Chin K, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul.27(13):3630-3640. Pubmedid: 33820783.
    • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
    • Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Dec.19(12):1441-1464. Pubmedid: 34902832.
    • Saltos A, Shafique M, Chiappori A. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Front Oncol. 2020 Jul.10:1074. Pubmedid: 32766139. Pmcid: PMC7378389.
    • Puri S, Shafique M. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020 Jan.9. Pubmedid: 32158484. Pmcid: PMC7048109.
    • Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
    • Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther. 2019 Mar.19(3):225-232. Pubmedid: 30657338.
    • Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist. 2019 Jul.24(7):887-e416. Pubmedid: 30996012. Pmcid: PMC6656474.
    • Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May.10:931-940. Pubmedid: 29760563. Pmcid: PMC5937504.
    • Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun.19(8):39. Pubmedid: 29931587.
    • Shafique MR, Lee MC, Han HS. Treatment of the Pregnant Patient with Breast Cancer. South Med J. 2017 Oct.110(10):627-631. Pubmedid: 28973702.
    • Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A. Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization. Surg Infect (Larchmt). 2014 Jun.15(3):182-186. Pubmedid: 24773230. Pmcid: PMC4696441.
    • Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Tr. 2014 Feb.20(2):257-263. Pubmedid: 24269380. Pmcid: PMC4140655.
  • Patient Comments

    Overall Satisfaction

    4.9

    297 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor